Sermorelin + Ipamorelin – 5mg / 5mg (3ml Pen)

Sermorelin + Ipamorelin 5mg/5mg (3ml Pen) – Growth Hormone Research Peptide Blend

Sermorelin + Ipamorelin is a dual-peptide research formulation combining a growth hormone-releasing hormone (GHRH) analogue with a synthetic growth hormone secretagogue. These compounds interact with two distinct receptor systems involved in regulating pituitary growth hormone secretion.

Sermorelin is a 29-amino-acid peptide corresponding to the biologically active region of human GHRH. Ipamorelin is a synthetic pentapeptide investigated for its relatively selective growth hormone-releasing activity through the growth hormone secretagogue receptor (GHS-R1a).

The combination is of interest in laboratory research examining pituitary function, endocrine selectivity, receptor interactions and growth hormone-related signalling pathways.

This formulation contains 5mg of Sermorelin and 5mg of Ipamorelin in a 3ml pen.

Understanding the Sermorelin and Ipamorelin Combination

Growth hormone secretion is regulated by several interacting physiological systems, including GHRH, somatostatin and ghrelin-related signalling.

Sermorelin and Ipamorelin act through different receptor mechanisms, allowing researchers to investigate these pathways together.

Sermorelin – GHRH Receptor Activation

Sermorelin corresponds to the first 29 amino acids of human growth hormone-releasing hormone.

It stimulates GHRH receptors located on anterior pituitary somatotroph cells, activating intracellular signalling pathways associated with growth hormone secretion.

Sermorelin has an established history in diagnostic and clinical endocrine research, particularly involving pituitary responsiveness and growth hormone regulation.

Ipamorelin – Selective Growth Hormone Secretagogue

Ipamorelin is a synthetic five-amino-acid peptide developed through research into growth hormone secretagogues.

It activates the GHS-R1a receptor, which is also involved in signalling by the naturally occurring hormone ghrelin.

Preclinical studies have demonstrated that Ipamorelin can stimulate growth hormone secretion with comparatively limited ACTH and cortisol responses compared with certain earlier growth hormone-releasing peptides.

This characteristic makes Ipamorelin particularly relevant to investigations examining endocrine selectivity.

Sermorelin + Ipamorelin and Muscle Growth Research

Growth hormone participates in several physiological processes associated with skeletal muscle, protein metabolism and tissue development.

Research involving growth hormone secretagogues helps scientists understand how different receptor pathways regulate endogenous hormone secretion.

Areas of scientific investigation include:

• Growth hormone regulation: Investigating interactions between GHRH and ghrelin receptor signalling.
• Muscle physiology: Examining hormonal mechanisms associated with skeletal muscle metabolism and tissue regulation.
• Protein metabolism: Studying endocrine pathways involved in protein turnover.
• IGF-1 signalling: Exploring relationships between growth hormone activity and insulin-like growth factor regulation.
• Pituitary function: Investigating hormone secretion through complementary receptor systems.
• Endocrine selectivity: Comparing growth hormone responses with changes in other hormonal pathways.

Although growth hormone signalling contributes to muscle physiology, clinical evidence has not established that this specific Sermorelin + Ipamorelin combination improves muscle mass, strength, recovery or athletic performance in humans.

Researchers examining related compounds can explore our collection of peptides for growth hormone and muscle physiology research, including individual peptides and combinations investigated for endocrine regulation, tissue metabolism and growth-related signalling.

Mechanism of Action

GHRH Receptor and cAMP Signalling

Sermorelin activates the growth hormone-releasing hormone receptor (GHRHR).

This stimulates intracellular cyclic adenosine monophosphate (cAMP) signalling, contributing to the activation of mechanisms involved in growth hormone release from pituitary somatotrophs.

The pathway is an important component of physiological growth hormone regulation.

Ghrelin Receptor and Calcium Signalling

Ipamorelin activates GHS-R1a, stimulating intracellular signalling pathways that include phospholipase C activity and calcium mobilisation.

Unlike Sermorelin, which acts through the GHRH receptor, Ipamorelin influences growth hormone secretion through the ghrelin receptor system.

The differences between these signalling mechanisms provide the scientific basis for investigating their combined activity.

Complementary Growth Hormone Pathways

Research involving GHRH analogues and growth hormone secretagogues has demonstrated enhanced growth hormone responses when both pathways are stimulated together under certain experimental conditions.

These findings suggest that GHRH and ghrelin receptor signalling can interact in regulating growth hormone release.

However, evidence supporting the general interaction between these pathways should not be interpreted as proof that this particular fixed-dose combination produces consistent synergistic effects or improved clinical outcomes.

Somatostatin Regulation

Somatostatin acts as an inhibitory regulator of growth hormone secretion.

The balance between stimulatory signals from GHRH and ghrelin receptor pathways and inhibitory somatostatin activity influences pituitary growth hormone responses.

Research involving these mechanisms contributes to understanding the regulation of pulsatile growth hormone secretion.

Scientific Research Applications

1. Dual-Receptor Endocrine Signalling

Sermorelin and Ipamorelin activate separate receptor systems involved in pituitary growth hormone secretion.

Their combined investigation offers a model for studying receptor interactions and complementary endocrine pathways.

2. Hormonal Selectivity

Ipamorelin has attracted research interest because of its comparatively selective growth hormone-releasing profile in preclinical studies.

Comparative investigations have reported less pronounced ACTH and cortisol stimulation than observed with GHRP-2 and GHRP-6 under certain conditions.

These findings do not establish that Ipamorelin or its combinations are free from endocrine adverse effects.

3. Pituitary Function Research

Sermorelin has a documented history in growth hormone stimulation research.

Ipamorelin provides an alternative receptor mechanism through which pituitary hormone secretion can be investigated.

Research involving both pathways contributes to understanding the regulation of growth hormone release.

4. IGF-1 and Tissue Regulation

Growth hormone influences the production of insulin-like growth factor-1 (IGF-1), which participates in cellular growth, tissue development and metabolic regulation.

Research into growth hormone secretagogue activity provides insight into the upstream endocrine mechanisms associated with this system.

5. Receptor Pharmacology

GHRH receptors and ghrelin receptors activate different intracellular signalling pathways.

Investigating their activity can help clarify receptor selectivity, endocrine responses and interactions between growth hormone regulatory systems.

Sermorelin + Ipamorelin Compared with Other Peptide Combinations

Sermorelin + Ipamorelin

Combines a 29-amino-acid GHRH analogue with a ghrelin receptor agonist investigated for comparatively selective growth hormone responses.

Sermorelin + GHRP-2

Combines the same GHRH analogue with GHRP-2, a growth hormone secretagogue associated with additional ACTH and cortisol responses in some studies.

Sermorelin + GHRP-6

Pairs Sermorelin with GHRP-6, a compound particularly associated with appetite-related ghrelin receptor signalling.

CJC-1295 No DAC + Ipamorelin

Combines Ipamorelin with a modified GHRH analogue designed to resist enzymatic degradation.

These distinctions are relevant when comparing peptide structure, receptor pharmacology and experimental endocrine responses.

Sermorelin + Ipamorelin Product Specifications

• Product: Sermorelin + Ipamorelin
• Quantity: 5mg Sermorelin + 5mg Ipamorelin
• Format: 3ml pen
• Classification: GHRH analogue and growth hormone secretagogue blend
• Sermorelin structure: 29-amino-acid peptide
• Ipamorelin structure: Synthetic pentapeptide
• Primary receptors: GHRHR and GHS-R1a
• Primary research focus: Growth hormone secretion and dual-receptor endocrine signalling
• Additional research areas: Pituitary function, hormonal selectivity, receptor pharmacology and muscle physiology
• Research status: Investigational peptide combination

Research Peptide Combinations from Coridion Sciences

Coridion Sciences maintains a specialist catalogue of research peptides and combination formulations investigated across endocrine regulation, cellular signalling and metabolic physiology.

Its research range includes individual compounds and peptide blends relevant to growth hormone biology, receptor pharmacology and tissue-related signalling.

Sermorelin + Ipamorelin 5mg/5mg is available in a 3ml pen format as part of the company’s research peptide collection.

Research Use Only: This formulation is intended exclusively for scientific and laboratory research. It is not approved for human consumption, medical treatment, muscle-building therapy or athletic performance enhancement. Findings involving the individual compounds do not establish the safety or efficacy of this specific combination.

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

Sermorelin record

Formal clinical documentation from diagnostic and paediatric endocrinology use.

Half-life constraint

The unmodified GHRH sequence degrades rapidly via dipeptidyl peptidase-4.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.